Skystar Bio (SKBI) is a China-based company that specializes in the research, development, production, and distribution of animal health and nutrition products. The company's products are primarily used to prevent and treat diseases in poultry, livestock, and pets, and include vaccines, antibiotics, feed additives, and probiotics.
Skystar Bio operates through two business segments: Veterinary Medicine and Feed Additives. The Veterinary Medicine segment produces vaccines and antibiotics that are used to prevent and treat diseases in livestock and poultry. The Feed Additives segment produces probiotics, enzymes, and other feed additives that promote animal growth and improve feed efficiency.
Skystar Bio's products are sold throughout China and in a number of international markets. The company's customers include large-scale poultry and livestock farmers, as well as feed manufacturers and distributors. Skystar Bio operates several production facilities, as well as research and development centers, in China.
Investors interested in Skystar Bio should be aware of the risks associated with investing in a Chinese company, including the risks of currency fluctuations, government regulations, and accounting practices. Additionally, the animal health and nutrition industry can be subject to factors such as disease outbreaks, which can impact the demand for Skystar Bio's products. It is important for investors to carefully evaluate the company's financial statements and track record before investing.
|
